BACKGROUND: Patients with neutropenic fever after 4-7 days of broad-spectrum antibiotics are given antifungals empirically. This strategy may lead to over-treatment. METHODS:Patients with hematological malignancies undergoing intensive chemotherapy or hematopoietic stem cell transplantation were randomized to two arms. Patients in the 'preemptive' arm had regular galactomannan (GM) assays, and received caspofungin, amphotericin or voriconazole (CAV) for persistent febrile neutropenia if they had two positive GM results, or a positive GM result and a computed tomography (CT) of the thorax suggestive of invasive pulmonary aspergillosis (IPA). Patients in the 'empirical' arm received CAV in accordance with established guidelines. RESULTS: Of 27 episodes in the preemptive arm, two cases of IPA were picked up by monitoring. In six episodes, CAV was started despite persistently negative GM readings. One additional patient received CAV for a false-positive GM. Of 25 episodes in the empirical arm, CAV was started empirically in 10, one of whom had CT features of IPA. By intent-to-treat and evaluable-episode analyses, respectively, the preemptive approach saved 11% and 14% of patients from empirical antifungals. Twelve-week survival was 85.2% in the preemptive arm and 84% in the empirical arm. CONCLUSIONS: A preemptive approach may reduce empirical antifungal use without compromising survival in persistently febrile neutropenic patients.
RCT Entities:
BACKGROUND:Patients with neutropenic fever after 4-7 days of broad-spectrum antibiotics are given antifungals empirically. This strategy may lead to over-treatment. METHODS:Patients with hematological malignancies undergoing intensive chemotherapy or hematopoietic stem cell transplantation were randomized to two arms. Patients in the 'preemptive' arm had regular galactomannan (GM) assays, and received caspofungin, amphotericin or voriconazole (CAV) for persistent febrile neutropenia if they had two positive GM results, or a positive GM result and a computed tomography (CT) of the thorax suggestive of invasive pulmonary aspergillosis (IPA). Patients in the 'empirical' arm received CAV in accordance with established guidelines. RESULTS: Of 27 episodes in the preemptive arm, two cases of IPA were picked up by monitoring. In six episodes, CAV was started despite persistently negative GM readings. One additional patient received CAV for a false-positive GM. Of 25 episodes in the empirical arm, CAV was started empirically in 10, one of whom had CT features of IPA. By intent-to-treat and evaluable-episode analyses, respectively, the preemptive approach saved 11% and 14% of patients from empirical antifungals. Twelve-week survival was 85.2% in the preemptive arm and 84% in the empirical arm. CONCLUSIONS: A preemptive approach may reduce empirical antifungal use without compromising survival in persistently febrile neutropenicpatients.
Authors: S-I Kimura; T Murata; Y Akahoshi; H Nakano; T Ugai; H Wada; R Yamasaki; Y Ishihara; K Kawamura; K Sakamoto; M Ashizawa; M Sato; K Terasako-Saito; H Nakasone; M Kikuchi; R Yamazaki; S Kako; J Kanda; A Tanihara; J Nishida; Y Kanda Journal: Eur J Clin Microbiol Infect Dis Date: 2015-01-11 Impact factor: 3.267
Authors: G Maschmeyer; W J Heinz; B Hertenstein; H-A Horst; C Requadt; T Wagner; O A Cornely; J Löffler; M Ruhnke Journal: Eur J Clin Microbiol Infect Dis Date: 2012-12-28 Impact factor: 3.267
Authors: Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett Journal: Clin Infect Dis Date: 2016-06-29 Impact factor: 9.079
Authors: S Harricharan; K Biederman; A M Bombassaro; A Lazo-Langner; S Elsayed; A Fulford; J A Delport; A Xenocostas Journal: Curr Oncol Date: 2018-04-30 Impact factor: 3.677
Authors: Ai Leng Khoo; Ying Jiao Zhao; Glorijoy Shi En Tan; Monica Teng; Jenny Yap; Paul Anantharajah Tambyah; Chin Hin Ng; Boon Peng Lim; Louis Yi Ann Chai Journal: J Fungi (Basel) Date: 2021-05-26